Introduction
LUTZ
Edited by: Luca Roncati, University of Modena and Reggio Emilia, ItalyReviewed by: Elizabeth De Gaspari, Adolfo Lutz Institute, Brazil; Srinivasa Reddy Bonam, University of Texas Medical Branch at Galveston, United StatesInterim analysis of phase I and phase II clinical trials of personalized vaccines made from autologous monocyte-derived dendritic cells (DCs) incubated with S-protein of SARS-CoV-2 show that this vaccine is safe and well tolerated. Our previous report also indicates that this vaccine can induce specific T-cell and B cell responses against SARS-CoV-2. Herein, we report the final analysis after 1 year of follow-up regarding its safety and efficacy in subjects of phase I and phase II clinical trials.